A Phase 2 interventional study of AMN107 in Gastrointestinal Stromal Tumors, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-02-23.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing nilotinib in Gastrointestinal Stromal Tumors — none open to participants now, none under way, none of them phase 3. nilotinib · Gastrointestinal Stromal Tumors.
Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, this one is the 7th largest by enrollment, is one of 6 that started in 2008, is one of 6 in phase 2, and was the 5th registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →None of the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors is open now. The open studies under Gastrointestinal Stromal Tumors, anywhere →
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2008.
This study's enrollment of 35 is below the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 35 across the 14 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 3 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
27 studies in Gastrointestinal Stromal Tumors by Novartis: none open now, none under way, none of them phase 3. Of 26 finished, 14 (54%) have results posted.
Among the 27 studies in Gastrointestinal Stromal Tumors by Novartis, this one is the 19th largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2008, is one of 13 in phase 2, and was the 9th registered.
Novartis’s Gastrointestinal Stromal Tumors studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 27 in Gastrointestinal Stromal Tumors:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of nilotinib in gastrointestinal stromal tumors patients who failed imatinib and sunitinib therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AMN107
Disease Control Rate (DCR) in all patients with either sunitinib-resistant GIST or in patients with GIST who are intolerant of sunitinib
Time frame: 24 weeks
DCR in patients with sunitinib-resistant GIST, Progression free survival (PFS), overall survival (OS), Objective response rate (ORR)
Time frame: 24 weeks
Safety
Time frame: 24 weeks
PK profile
Time frame: 24 weeks
The record gives a start of Sep 2008, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Gastrointestinal Stromal Tumors →